Adma Biologics reports preliminary FY24 revenue $417M-$425M, consensus $423.19M

ADMA Biologics (ADMA) announced its preliminary unaudited full year 2024 revenue and provided a business update. Based on unaudited financial information, ADMA preliminarily estimates that its total revenue for the full year ended December 31, 2024 will be between $417-425 million. ADMA’s total cash holdings at year-end 2024 grew to greater than $100 million, representing a net cash surplus relative to the $75 million of total debt currently outstanding with Ares Capital.